4//SEC Filing
Morabito Christopher 4
Accession 0001104659-24-008327
CIK 0001454789other
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 5:03 PM ET
Size
15.5 KB
Accession
0001104659-24-008327
Insider Transaction Report
Form 4
Morabito Christopher
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-01-29−9,200→ 90,000 totalExercise: $3.87Exp: 2032-07-31→ Common Stock (9,200 underlying) - Exercise/Conversion
Common Stock
2024-01-26$3.87/sh+800$3,096→ 800 total - Sale
Common Stock
2024-01-26$11.02/sh−800$8,812→ 0 total - Exercise/Conversion
Common Stock
2024-01-29$3.87/sh+9,200$35,604→ 9,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−800→ 99,200 totalExercise: $3.87Exp: 2032-07-31→ Common Stock (800 underlying) - Sale
Common Stock
2024-01-29$11.15/sh−9,200$102,552→ 0 total
Footnotes (4)
- [F1]This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.02, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
Documents
Issuer
Astria Therapeutics, Inc.
CIK 0001454789
Entity typeother
Related Parties
1- filerCIK 0001859284
Filing Metadata
- Form type
- 4
- Filed
- Jan 29, 7:00 PM ET
- Accepted
- Jan 30, 5:03 PM ET
- Size
- 15.5 KB